TOKYO–(BUSINESS WIRE)–Heartseed Inc. (hereinafter Heartseed), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for the treatment of heart failure (HF), today announced it has entered into agreement with ITOCHU CHEMICAL FRONTIER Corporation (headquartered in Minato-ku, Tokyo; President & CEO Tsutomu Miyazaki, […]